小细胞肺癌中组蛋白甲基转移酶KMT2D/MLL2频繁出现失活突变:CALGB 151111(Alliance)
研究对18例原发小细胞肺癌和7个细胞系进行全外显子测序,并在40例原发肿瘤和48个细胞系中重测序基因面板,发现KMT2D在8%肿瘤和17%细胞系中携带截短型突变,伴蛋白水平及H3K4单甲基化降低,提示转录增强子调控异常可能参与小细胞肺癌发生。
要点
- KMT2D在8%原发小细胞肺癌和17%细胞系中发生截短型突变。
- KMT2D突变细胞系中KMT2D蛋白水平降低,H3K4单甲基化减少。
- CREBBP、EP300、CHD7和PBRM1等增强子调控相关基因亦存在突变。
核心结论
- 数据表明KMT2D是小细胞肺癌主要突变基因之一,并提示转录增强子调控异常可能促进小细胞肺癌发生。
研究设计与样本
- 对18例原发小细胞肺癌和7个细胞系及匹配正常对照进行全外显子测序。
- 在40例原发小细胞肺癌和48个细胞系中对一组基因进行重测序。
主要发现
- KMT2D在8%的小细胞肺癌肿瘤和17%的小细胞肺癌细胞系中表现为无义、移码或剪接位点截短型突变。
- 人小细胞肺癌细胞系中KMT2D突变与赖氨酸甲基转移酶2D蛋白水平降低及组蛋白H3赖氨酸4单甲基化减少相关。
- 其他转录增强子调控相关基因如CREBBP、EP300、CHD7及染色质重塑基因PBRM1亦发现突变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: SCLC is a lethal neuroendocrine tumor type that is highly prone to metastasis. There is an urgency to understand the mutated genes that promote SCLC, as there are no approved targeted therapies yet available. SCLC is rarely resected, limiting the number of samples available for genomic analyses of somatic mutations. METHODS: To identify potential driver mutations in human SCLC we sequenced the whole exomes of 18 primary SCLCs and seven cell lines along with matched normal controls. We extended these data by resequencing a panel of genes across 40 primary SCLCs and 48 cell lines. RESULTS: We report frequent mutations in the lysine methyltransferase 2D gene (KMT2D) (also known as MLL2), a key regulator of transcriptional enhancer function. KMT2D exhibited truncating nonsense/frameshift/splice site mutations in 8% of SCLC tumors and 17% of SCLC cell lines. We found that KMT2D mutation in human SCLC cell lines was associated with reduced lysine methyltransferase 2D protein levels and reduced monomethylation of histone H3 lysine 4, a mark associated with transcriptional enhancers. We also found mutations in other genes associated with transcriptional enhancer control, including CREB binding protein gene (CREBBP), E1A binding protein p300 gene (EP300), and chromodomain helicase DNA binding protein 7 gene (CHD7), and we report mutations in additional chromatin remodeling genes such as polybromo 1 gene (PBRM1). CONCLUSIONS: These data indicate that KMT2D is one of the major mutated genes in SCLC, and they point to perturbation of transcriptional enhancer control as potentially contributing to SCLC.
引用
- Augert A, Zhang Q, Bates B, et al. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance). J Thorac Oncol. 2016. PMID: 28007623. doi:10.1016/j.jtho.2016.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。